



**Universiteit
Leiden**
The Netherlands

Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Grootveld, R. van; Masarotto, V.; Borne, P.A. von dem; Blijlevens, N.M.A.; Chitu, D.A.; Beek, M.T. van der; ... ; Boer, M.G.J. de

Citation

Grootveld, R. van, Masarotto, V., Borne, P. A. von dem, Blijlevens, N. M. A., Chitu, D. A., Beek, M. T. van der, ... Boer, M. G. J. de. (2023). Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome. *Bmc Infectious Diseases*, 23(1).
doi:10.1186/s12879-023-08013-5

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/3576172>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH

Open Access



Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Rebecca van Grootveld^{1*}, Valentina Masarotto^{2†}, Peter A. von dem Borne³, Nicole M. A. Blijlevens⁴, Dana A. Chitu⁵, Martha T. van der Beek¹, Marta Fiocco^{2,6†} and Mark G. J. de Boer^{7†}

Abstract

Purpose Study objectives were to estimate the cumulative incidence of death due to different causes of death (CODs) and investigate the effect of invasive aspergillosis (IA) on each separate COD in a cohort of older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) included in the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) 43 randomized controlled trial.

Methods Pre-collected data from the trial was obtained from the HOVON data center and relevant clinical information was extracted. The cumulative incidence of death due to different CODs was estimated with a competing risk model and the association between each COD and prognostic factors, including IA, were investigated with a cause-specific hazard Cox regression model.

Results In total 806 patients were included, mean age of 70 years and 55% were male. The cumulative incidences of death due to leukaemia or infection at 3, 6, 12 and 36 months were 0.06, 0.11, 0.23, 0.42 and 0.17, 0.19, 0.22, 0.25 respectively. Incidence of IA was 21% and diagnosis of IA up until the final chemotherapy cycle was associated with an increased risk of dying from leukaemia (cause-specific hazard ratio ($c_{\text{S}}\text{HR}$): 1.75, 95% CI 1.34–2.28) and a trend was seen for infection ($c_{\text{S}}\text{HR}$: 1.36, 95% CI 0.96–1.91).

Conclusion Leukaemia was the most likely cause of death over time, however in the first year after diagnosis of AML or high-risk MDS infection was the most likely cause of death. Patients with IA had a relatively increased risk of dying from leukaemia or infection.

Keywords Aspergillosis, Invasive pulmonary aspergillosis, Invasive fungal infection, Acute myeloid leukaemia, Myelodysplastic syndromes, Aged

[†]Rebecca van Grootveld and Valentina Masarotto contributed equally to this work.

[†]Marta Fiocco and Mark G. J. de Boer contributed equally to this work.

*Correspondence:

Rebecca van Grootveld
r.van_grootveld@lumc.nl

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

The incidence of invasive aspergillosis (IA) in patients with haematological malignancies ranges from 4 (with prophylaxis) to 11% (without prophylaxis) during remission induction chemotherapy and is approximately 8% after allogeneic stem cell transplantation (SCT) [1]. In patients with acute myeloid leukaemia (AML) the most common risk factor for development of IA is prolonged and severe neutropenia which is induced by AML or by intensive chemotherapy [2]. In addition, lack of response to chemotherapy and age have been reported to be risk factors for development of IA [3–5].

AML is mostly seen in older patients with a median age of around 70 years [6, 7]. The 5-year survival for patients older than 15 years diagnosed with AML in Europe in 2000–2007 was 17% but survival rates decreased steeply with age [8]. Most patients with AML have active leukaemia at time of death. Other reported causes of death (CODs) include transplant related complications, infection (pneumonia in particular), bleeding, or other causes [9–14]. The contribution of IA to COD in patients with AML is difficult to quantify, because IA has multiple risk factors and these risk factors also directly contribute to AML treatment failure, complications and mortality [15, 16].

In the past years overall survival has improved for younger AML patients, mostly due to improved supportive care and improvements of allogeneic-SCT [17–19]. Conversely, for older patients with AML limited progress has been made [17–19]. This can be explained by patient and disease specific factors. Older patients with AML are more likely to have comorbidities, poor performance status, less tolerance to intensive chemotherapy and a higher incidence of poor prognostic factors, such as unfavourable cytogenetics and secondary leukaemia after myelodysplastic syndrome (MDS) [6, 20, 21]. Moreover, older patients are more susceptible for infections due to immunosenescence, a gradual decrease in immune system function associated with physiological aging that affects both the innate and the adaptive immune system, malnutrition and age related physiological changes [22, 23].

Study objectives were to estimate the cumulative incidence of death due to different CODs and to investigate the effect of IA on each separate COD in a cohort of older patients with AML (≥ 61 years) or high-risk MDS included in the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) 43 randomized controlled trial. The HOVON focuses on improving treatment methods for adult patients with malignant haematological disorders by implementing randomized controlled trials.

Materials and methods

Study design

Pre-collected data from the HOVON-43 randomized controlled trial [13] was requested from the HOVON data center. This trial included patients with AML or high-risk MDS. From all patients clinical information was extracted about diagnosis, treatment, response to treatment, survival and COD. The trial data contained an infection form in which all infections were registered during each chemotherapy treatment cycle. From the infection form, all patients with an occurrence of IA were identified. A competing risk model was applied to estimate the cumulative incidence of death with different competing events (different CODs). A cause specific hazard Cox regression model was used to investigate the association between survival time and multiple covariates.

All ethical considerations were within the intended use of the HOVON-43 randomized controlled trial and in accordance to the ethical principles as posed in the declaration of Helsinki as well as current national legislation.

HOVON-43 trial data

Data was previously collected during the HOVON-43 randomized controlled trial that was performed from 2000–2006 [13]. This trial was performed to determine the optimal dose of daunorubicin in older patients (≥ 61 years old) treated for AML or high-risk MDS. In short, after diagnosis eligible patients were randomly assigned to receive a first cycle of conventional or escalated dose of daunorubicin in combination with cytarabine. Next, a second cycle of treatment was administered in both groups consisting of high dose cytarabine. After each cycle of remission induction chemotherapy response was assessed. Patients in complete remission after the second cycle could undergo a reduced intensity allogeneic-SCT if an HLA-matched donor had been identified. Otherwise, patients were randomly assigned to receive post remission chemotherapy with gemtuzumab ozogacimin (GO) or no treatment. Patients who were not in complete remission or who experienced a serious adverse event were not further randomized. Follow-up was performed until five years after the second chemotherapy cycle. Patients did not receive antifungal prophylaxis. At the time, chemoprophylaxis to prevent filamentous fungal infections was not standard practice.

Patient population and data collection

A selection of baseline patient characteristics was made to investigate the effect of these prognostic factors on different CODs before start of chemotherapy. We obtained the following baseline variables: date of birth, gender, WHO performance status, AML or MDS, white blood

cell (WBC) count at diagnosis, prior haematological or oncological disease, previous chemotherapy or radiotherapy, bone marrow cellularity, bone marrow fibrosis. Time dependent variables included outcome (death/alive), COD and occurrence of IA.

From the infection form the variable 'occurrence of IA' was created by identification of all patients with an occurrence of IA at any time point in the treatment schedule. Cases in which the diagnosis of IA was uncertain ($n=72$) were discussed by two investigators (MdB and RvG) and final decision was based on consensus (17 IA; 55 no IA). In case consensus would not be reached, a third expert was consulted (MvdB). In most cases that were discussed only treatment with an antifungal agent was registered without mention of IA. That was not considered enough evidence for diagnosis IA. The uncertain cases that were classified as IA had a lung abnormality on imaging and were treated with an antifungal agent. The timepoint of IA was estimated from the chemotherapy cycle date in which the occurrence of IA was registered. Diagnosis of IA was made by the treating physician at the time. The data did not contain information about clinical characteristics, which diagnostic test was performed for the diagnosis of IA, or certainty of diagnosis according to EORTC/MSGERC guidelines [24].

In the dataset the COD was grouped into the following categories: leukaemia (including high-risk MDS), pneumonitis, infection, haemorrhage, veno-occlusive disease, secondary malignancy, other COD or unknown. Cause of death was recorded according to the clinical judgement of the treating physician at the time of death, as the rate of autopsy in this patient population was very low. In most patients the COD was described in a free text field as well. By checking the description of the COD, a few misclassified COD were reclassified.

For modelling purposes different CODs were grouped together. The variables 'infection' and 'other COD' were grouped together ('infection and other COD'), because 'other COD' included 12/70 patients with infection as one of the documented CODs as well. In total, 158/216 (73%) in the group 'infection and other COD' had an infection. The variables 'pneumonitis', 'haemorrhage', 'veno-occlusive disease', 'secondary malignancy' and 'unknown' were grouped together as 'miscellaneous'. In haematology patients pneumonitis is mostly defined as lung inflammation induced by chemotherapy. Therefore pneumonitis was not considered an infection.

Statistical methods

In this study, a competing risk model [25] was applied to estimate the cumulative incidence of death with the competing events 'leukaemia', 'infection and other COD', and 'miscellaneous'.

To study the association between each competing event ('leukaemia', 'infection and other COD' and 'miscellaneous') and prognostic factors a Cox proportional-hazard model [26] was estimated. Time fixed prognostic factors included in the model were AML or high-risk MDS, prior haematological or oncological disease, previous chemo- or radiotherapy, WBC count at diagnosis and age. Invasive aspergillosis was included in the model as time dependent. The last documented cycle of chemotherapy was selected for the diagnosis of IA. If a patient did not have IA from the time of inclusion until the end of the final chemotherapy treatment cycle, the patient was registered as not having IA. Hazard ratios (HR) along with their 95% confidence intervals (CI) were reported. A p -value of <0.05 was considered statistically significant. Bone marrow cellularity and bone marrow fibrosis were not included as variable in the Cox proportional hazard model due to a high number of missing data, as was WHO performance status, because values were similar for all patients.

All analyses were performed in R software environment (<https://www.R-project.org/>) with the *mstate* library [27].

Results

The HOVON-43 trial included a total of 866 patients. Overall, 60 patients were a priori excluded from the analysis (Table 1).

Table 1 summarises the patient characteristics at baseline for the included 806 patients. The mean age at the time of diagnosis was 70 years (range: 61–88). In total, 710 (88.1%) patients died during the study period. Table 2 displays the number of patients and percentage for each COD. A total of 171 (21.2%) patients developed IA during follow-up, of whom 40 recovered. The remaining 131 patients had IA up until in their final chemotherapy cycle and of these patients 121 (92.4%) died. Most patients developed IA during remission induction chemotherapy in cycle I and II (Table 3). Table 2 shows the number and percentage of patients who had IA up until their final chemotherapy treatment cycle for the different CODs.

Figure 1 displays the cumulative incidence of death for the different CODs. As expected from the summary presented in Table 2, leukaemia was the most likely COD over time. However, the probability of dying from an infection or other COD in the first year after diagnosis of AML or high-risk MDS was higher than the probability of dying from another cause.

The cause specific HRs (C_S HR) estimated from the Cox model are provided in Table 4. Diagnosis of IA in the final cycle of treatment was associated with an increased risk of dying due to 'leukaemia' (C_S HR 1.750 (95% CI 1.341–2.282)) and less markedly due to 'infection and other COD' (C_S HR 1.359 (95% CI 0.958–1.909)). Age was

Table 1 Descriptive statistics of the selected relevant variables at time of diagnosis of AML or high-risk MDS

Characteristics	n (%)
Total	806
Age (mean)	70
Age	
≤70 years	427 (53)
>70 years	379 (47)
Sex	
Male	441 (55)
Female	365 (45)
AML or MDS	
AML	677 (84)
MDS	129 (16)
WHO performance status	
WHO 0	262 (33)
WHO 1	448 (56)
WHO 2	83 (10)
WHO 3	2 (0.2)
Bone marrow cellularity	
Low	60 (7)
Medium	123 (15)
High	430 (53)
WBC count (× 10 ⁹ cells/L)	
1st quantile	2
Median	5.5
3rd quantile	27
Prior haematological or oncological disease	
No	747 (93)
Yes	59 (7)
Previous chemo- or radiotherapy	
No	596 (74)
Yes	210 (26)
Bone marrow fibrosis	
No	497 (62)
Yes	112 (14)

AML acute myeloid leukaemia, MDS myelodysplastic syndrome, WBC white blood cell. Unknown entry is not displayed

The HOVON trial included 866 patients of whom 60 were excluded from the analysis. Patients were excluded from the analysis for the following reasons: incomplete records (n = 33), time of diagnosis and or time of follow-up not documented correctly (n = 8), registered twice (n = 4), missing informed consent (n = 1), diagnosis of acute promyelocytic leukaemia (n = 6), no AML (n = 4), diagnosis of refractory anaemia with an international prognostic score of less than 1.5 (low-risk MDS) (n = 1), previously treated AML (n = 1), medical history of malignant lymphoma (n = 1) or concurrent liver cancer (n = 1)

included as a categorical variable in the model. Older age (>70 years) seemed to have a protective effect for death due to leukaemia (C_sHR 0.745 (95% CI 0.614–0.904)). Higher WBC count at diagnosis was significantly associated with an increased risk of dying from leukaemia. Note that WBC count was included as a linear term in

Table 2 Cause of death/alive grouped by patients with or without invasive aspergillosis up until their final chemotherapy cycle

Cause of death/Alive	With IA, n (%)	Without IA, n (%)	Total, n (%)
Total (known)	131 (100)	675 (100)	806 (100)
Leukaemia	59 (45)	321 (47.6)	380 (47.1)
Pneumonitis	10 (7.6)	22 (3.3)	32 (4)
Infection	31 (23.7)	115 (17)	146 (18.1)
Haemorrhage	5 (3.8)	30 (4.4)	35 (4.3)
Veno-occlusive disease	1 (0.8)	1 (0.1)	2 (0.2)
Secondary malignancy	1 (0.8)	9 (1.3)	10 (1.2)
Other	9 (6.9)	61 (9)	70 (8.7)
Unknown	5 (3.8)	30 (4.4)	35 (4.3)
Alive	10 (7.6)	86 (12.7)	96 (11.9)

The variables 'infection' and 'other cause of death (COD)' were grouped together ('infection and other COD'), because 'other COD' included 12/70 patients with infection as one of the CODs as well. The variables 'pneumonitis', 'haemorrhage', 'veno-occlusive disease', 'secondary malignancy' and 'unknown' were group together as 'miscellaneous', because of the relatively small number of patients in all categories

the model, implying that the HR indicates the increase in risk for every unit of WBC count.

Discussion

Cumulative incidence of death and effect of IA on death

We found that from 12 months onwards after diagnosis of AML or high-risk MDS leukaemia was the most likely cause of death. However, in the first 12 months after diagnosis of AML or high-risk MDS the probability of dying from an infection or other COD was higher than the probability of dying from another cause. By estimating the cumulative incidence with a competing risk model we were able to estimate the cumulative incidence for each COD and study the effect of prognostic factors on these CODs ('leukaemia', 'infection and other COD', and 'miscellaneous'). With regard to IA, patients with IA up until their final chemotherapy cycle had an increased risk of dying from 'leukaemia' or 'infection and other COD'. This is in concordance with a study that reported that IA was associated with a higher risk of death in patients with AML as compared to patients without IA [10]. Another study showed that no development of IA during first remission induction chemotherapy was associated with complete remission and complete remission at three years [28].

The predisposing host risk factor for IA in patients with AML or MDS is prolonged and severe neutropenia [2, 29]. Neutropenia can be caused by intensive cytotoxic treatment or by the leukaemia itself. Patients with refractory leukaemia are at highest risk of developing IA, because they might be treated with multiple

Table 3 Chemotherapy treatment cycle in which invasive aspergillosis was first diagnosed

Chemotherapy treatment cycle	Number of patients that underwent chemotherapy treatment cycle, n	Cases of IA not recovered by the final chemotherapy cycle, n (%)	All IA cases, n (%)
Total	795	131 (16)	171 (22)
Cycle I	795	46 (6)	83 (10)
Cycle II	577	84 (15)	87 (15)
GO cycle I	114	0 (0)	0 (0)
GO cycle II	92	1 (1)	1 (1)
GO cycle III	65	0 (0)	0 (0)

Cycle I and II remission induction chemotherapy cycle I and II, GO cycle I, II and III gemtuzumab ozogacinin, post remission chemotherapy cycle I, II and III, IA invasive aspergillosis

Of note: Post-remission, 49 patients received reduced intensity allogeneic-stem cell transplantation (SCT) consolidation therapy. There were no data available about infections, or IA in particular, that occurred during or after SCT

chemotherapy cycles and they might be neutropenic due to the underlying leukaemia [29]. These patients also have a higher risk of dying, because the presence of underlying disease, cytotoxic treatment and immunocompromised status can all cause severe complications that lead to death. Invasive aspergillosis may often not be the direct COD. If death occurs in a patient suffering from multiple diseases, each disease can be either the direct COD (attributable), can have contributed to the events that lead to death (contributable), or be unrelated to death [30]. Despite, assessing the COD in patients with IA remains difficult and is further complicated because there is no universal approach to discriminate between association and causation with regard to IA and death [30].

Incidence of invasive aspergillosis in older patients with AML or high-risk MDS

The incidence of IA in this cohort was 21% and IA occurred mostly during remission induction chemotherapy. This is similar to findings in other studies described in a recent meta-analysis, although incidences of IA ranged from 3.2%–43.1% during remission induction chemotherapy in patients without prophylaxis [1]. In this meta-analysis a crude incidence of 11.1% was reported during remission induction chemotherapy in patients without prophylaxis [1].

Influence of age and other co-variables

The results from this study suggest that older age (>70 years) had a slight protective effect with regard to the risk of dying due to leukaemia itself ($c_{s}HR$: 0.745 (95% CI 0.641–0.904)). This was an unexpected finding since a higher incidence of poor prognostic factors is mostly found in older patients [6, 20, 21]. In an assessment of the outcomes of patients with secondary AML included in 13 EORTC trials conducted between 1986 and 2008, patients >60 years did not have better

outcomes than patients >70 years. On the other hand, in this study WHO performance status was strongly associated with overall survival with a median of 0.8 years in patients with WHO performance status 0–1 and 0.4 years in patients with WHO performance status 2–4 [19]. It is unclear how these results should be explained. In our study, WHO performance status was comparable in patients ≤ 70 years and >70 years. Thus, WHO performance status does not explain the slight protective effect of older age with regard to the risk of dying to leukaemia itself. The finding suggests that there might be a confounder, for example, differences in AML or MDS cytogenetics. Alternatively, the generalizability of the study might be limited by characteristics of the studied patient population. The finding that older age is protective may be biased by the phenomenon that less fit older patients may not have wanted to participate in the trial.

Antifungal prophylaxis

At the time the HOVON-43 trial was performed antifungal prophylaxis was not prescribed to patients. Nowadays, *Aspergillus*-effective antifungal prophylaxis is standard of care in patients with AML or high-risk MDS undergoing intensive chemotherapy. Current national and international guidelines advise antifungal prophylaxis during prolonged neutropenia following chemotherapy for patients who are at high risk for IA [31–34]. In general, antifungal prophylaxis is not recommended beyond remission induction chemotherapy [32].

From the observed overall incidence of IA of 21% it becomes clear that antifungal prophylaxis would have been indicated in this group, in particular during remission induction chemotherapy. Only one patient developed IA during post remission chemotherapy. The reported incidence of IA during consolidation chemotherapy is low, around 2–3% [35, 36]. A retrospective multicentre study showed that antifungal prophylaxis during consolidation chemotherapy decreased the




Fig. 1 Cumulative incidence of different causes of death. The cumulative incidence of an event is displayed graphically as the plot of the cumulative incidence function. It displays the probability that a specific event (death due to leukaemia, infection and other cause of death (COD) or miscellaneous) has occurred by a specific time. Other COD included the CODs: leukaemia in combination with: infection (n = 8), infection and haemorrhage (n = 2), infection and multi organ failure (n = 1), haemorrhage (n = 2), pneumonitis (n = 2), cardiac disease (n = 2), respiratory insufficiency and pneumonitis (n = 1), respiratory and cardiac insufficiency (n = 1), pulmonary embolism (n = 1) or ileus (n = 1), and infection, renal failure and haemorrhage (n = 1), multiorgan failure (n = 8), liver failure (n = 1), renal failure (n = 1), cardiac disease (n = 14), respiratory insufficiency (n = 4), cardiac disease and haemorrhage (n = 1), acute respiratory distress syndrome (n = 2), graft versus host disease (n = 2), encephalopathy (n = 2), cerebrovascular accident (n = 3), pulmonary embolism (n = 2), ileitis (n = 1), hypoxic brain damage (n = 1), progressive supranuclear paralysis (n = 1), subdural bleeding (n = 1), progressive degeneration of general state (n = 1), euthanasia (n = 2) and suicide (n = 1). Miscellaneous included the CODs: pneumonitis, haemorrhage, veno-occlusive disease, secondary malignancy and unknown

Table 4 Estimated cause-specific hazard ratio along with their 95% confidence interval for the different causes of death 'leukaemia', 'infection and other cause of death' and 'miscellaneous'

Leukaemia	c _s HR	95% CI	p-value
IA up until final chemotherapy cycle	1.750	1.341–2.282	<0.001*
AML/MDS (MDS)	0.988	0.771–1.266	0.923
WBC count	1.002	1.001–1.004	0.054*
No prior haematological or oncological disease	0.938	0.751–1.169	0.567
No previous chemo- or radiotherapy	0.849	0.560–1.288	0.443
Age > 70	0.745	0.614–0.904	0.003*
Infection and other COD	c _s HR	95% CI	p-value
IA up until final chemotherapy cycle	1.359	0.958–1.909	0.085
AML/MDS (MDS)	0.827	0.623–1.210	0.403
WBC count	1.002	0.996–1.005	0.106
No prior haematological or oncological disease	1.318	0.978–1.775	0.068
No previous chemo- or radiotherapy	1.320	0.870–2.003	0.191
Age > 70	0.961	0.757–1.210	0.747
Miscellaneous	c _s HR	95% CI	p-value
IA up until final chemotherapy cycle	1.085	0.621–1.895	0.773
AML/MDS (MDS)	0.942	0.603–1.453	0.792
WBC count	0.999	0.997–1.005	0.733
No prior haematological or oncological disease	0.934	0.626–1.393	0.738
No previous chemo- or radiotherapy	0.538	0.231–1.258	0.153
Age > 70	0.855	0.607–1.206	0.373

*Statistically significant, AML acute myeloid leukaemia, COD cause of death, c_sHR cause specific hazard ratio, IA invasive aspergillosis, MDS myelodysplastic syndrome, WBC white blood cell count, 95% CI 95% confidence interval

incidence of IA [35]. In this study, IA was diagnosed in 34/1137 (2.9%) who did not receive antifungal prophylaxis and in 22/1451 (1.5%) who did receive prophylaxis ($p < 0.01$) [35]. The number needed to treat to prevent IA was 71. The authors concluded that antifungal prophylaxis during consolidation chemotherapy may be required in older patients receiving high dose cytarabine, as age ≥ 60 years and treatment with high dose cytarabine were both independently associated with mortality. This only partly applied to our cohort. Although antifungal prophylaxis decreases the incidence of IA, IA cannot be fully prevented [1]. As an alternative to standard prophylaxis, screening strategies using a galactomannan serum assay can be deployed in high risk groups such as this study cohort [37].

Study strengths and limitations

Strengths of the study included the size of the study population and the quality of the data which was prospectively collected during a randomized controlled trial. However, it should be considered that the cohort dates from 2006 and since then advances in diagnostics and treatment of IA as well as improvements in prophylactic strategies have been made. Still though, the competing

risk analysis enabled us to study the effect of IA on mortality for each separate COD ('leukaemia', 'infection and other COD' and 'miscellaneous'). Furthermore, we focused on IA as COD in older patients with AML or high-risk MDS. Though there are some limitations. First, IA was described in the infection form, but in a small number of patients the diagnosis was uncertain. These cases were discussed and final decision was based on consensus. Secondly, no information was available about clinical characteristics, diagnostic tests that were performed, or the certainty of diagnosis. We were dependent on the diagnosis of IA that was made by the treating physician at the time and registered in the infection form. However, even though exact certainty of the diagnosis of IA could not be established in this cohort, as is more often the case in real-life clinical practice, the diagnosis (and treatment) of IA are usually not made and reported without consideration of host characteristics, imaging and clinical signs and symptoms. Thirdly, the COD was based on clinical diagnosis and not autopsy. In some cases, IA itself was the COD, but numbers are uncertain as COD infection was not always further specified. Fourthly, for modelling purposes different COD needed to be grouped together.

Conclusions

In this cohort of older patients with AML or high-risk MDS, leukaemia was the most likely cause of death over time. However, in the first year after diagnosis of AML or high-risk MDS infection was the most likely cause of death. The high incidence of IA that was found underscores the indication for antifungal prophylaxis in this older patient population, in particular during remission induction chemotherapy. Since diagnosis of IA is not made and reported lightly in this population, the absence of the currently used EORTC classification system at the time, may only have had limited influence on the findings of this study. Patients with IA up until their final chemotherapy cycle had an increased risk of dying from leukaemia or infection, although the exact role IA played in the COD is unknown. Our results are suggestive of a contributable effect of IA, but further research is necessary that focusses on a universal classification to determine which role IA plays in the COD and the implementation of such a classification. Determining whether death is attributable, contributable or unrelated to IA will enhance our understanding of IA, and can lead to improved management of patients with leukaemia and IA.

Acknowledgements

We thank the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) for providing data from the HOVON-43 trial. We thank Dr. R.J. van de Peppel, Prof. Dr. O.M. Dekkers, Dr. C.J.M. Halkes, Prof. Dr. J.H. Veelken, Dr. A.H.W. Bruns, Prof. Dr. F. van de Veerndonk and Dr. B.J.A. Rijnders for their contribution in study conceptualisation.

Author contributions

RvG and VM were responsible for extracting and analysing data, interpreting the results, drafting and reviewing the manuscript. MdB and MF were responsible for the study design, requesting data from the HOVON data center, interpreting the results, drafting and reviewing the manuscript. PvdB was responsible for interpreting the results and provided feedback on the manuscript. DC was responsible for extracting data from the HOVON data center. MvdB and NB provided feedback on the manuscript. All authors read and approved the final manuscript.

Funding

No funding was received for conducting this study.

Availability of data and materials

The data that support the findings of this study are available from the HOVON data center but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the HOVON data center.

Declarations

Ethics approval and consent to participate

All ethical considerations in this post-hoc study were within the intended use of the HOVON-43 randomized controlled trial and in accordance to the ethical principles as posed in the declaration of Helsinki as well as current national legislation. The HOVON-43 study was approved by the ethics committee of the Erasmus University Rotterdam/Academic Hospital Rotterdam (METC EUR/AZR, 30 August 2000) and the ethics committee of each participating institution (<https://hovon.nl/en/trials/ho43>) [13]. Written informed consent was

originally obtained from the participants for the HOVON-43 study for which the data were collected.

Consent for publication

Not applicable.

Competing interests

No potential financial or non-financial competing interest was reported by any of the authors.

Author details

¹Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. ²Mathematical Institute, Leiden University, Leiden, The Netherlands. ³Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands. ⁴Department of Haematology, Radboud University Medical Center, Nijmegen, The Netherlands. ⁵Department of Haematology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁶Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands. ⁷Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.

Received: 15 August 2022 Accepted: 18 January 2023

Published online: 06 February 2023

References

- van de Peppel RJ, Visser LG, Dekkers OM, de Boer MGJ. The burden of Invasive Aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review. *J Infect*. 2018;76:550–62. <https://doi.org/10.1016/j.jinf.2018.02.012>.
- Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. *Drugs*. 2007;67:1567–601. <https://doi.org/10.2165/00003495-200767110-00004>.
- Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. *Br J Haematol*. 2007;139:519–31. <https://doi.org/10.1111/j.1365-2141.2007.06812.x>.
- Girmeria C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Clin Infect Dis*. 2009;49:1226–36. <https://doi.org/10.1086/605665>.
- Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. *Med Mycol*. 2011;49:681–7. <https://doi.org/10.3109/13693786.2011.557668>.
- Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stöckelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood*. 2009;113:4179–87. <https://doi.org/10.1182/blood-2008-07-172007>.
- Dimmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012. *Leukemia*. 2016;30:24–31. <https://doi.org/10.1038/leu.2015.188>.
- De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EURO-CARE-5 population-based study. *Eur J Cancer*. 2015;51:2254–68. <https://doi.org/10.1016/j.ejca.2015.08.003>.
- Stalfelt AM, Brodin H, Pettersson S, Eklöf A. The final phase in acute myeloid leukaemia (AML): a study of cause of death, place of death and type of care during the last week of life. *Leuk Res*. 2001;25:673–80. [https://doi.org/10.1016/s0145-2126\(01\)00005-4](https://doi.org/10.1016/s0145-2126(01)00005-4).
- Michallet M, Bénét T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. *Eur J Clin Microbiol Infect Dis*. 2012;31:991–7. <https://doi.org/10.1007/s10096-011-1397-5>.
- Cheng HW, Li CW, Chan KY, Au HY, Chan PF, Sin YC, et al. End-of-life characteristics and palliative care provision for elderly patients suffering from

- acute myeloid leukemia. *Support Care Cancer*. 2015;23:111–6. <https://doi.org/10.1007/s00520-014-2333-x>.
12. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. *Ann Am Thorac Soc*. 2013;10:432–40. <https://doi.org/10.1513/annalsats.201304-097oc>.
 13. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med*. 2009;361:1235–48. <https://doi.org/10.1056/nejmoa0901409>.
 14. Foster J, Blonquist TM, El-Jawahri A, Fathi AT, Amrein PC, Sadrzadeh H, et al. The End of life for patients with acute myeloid leukemia (AML)—a single center experience. *Blood*. 2015;126:3318. <https://doi.org/10.1182/blood.V126.23.3318.3318>.
 15. van de Peppel RJ, Dekkers OM, von dem Borne PA, de Boer MG. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. *Med Mycol*. 2014;52:699–705. <https://doi.org/10.1093/mmy/myu036>.
 16. van de Peppel RJ, von dem Borne PA, le Cessie S, de Boer MGJ. A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS. *Bone Marrow Transplant*. 2017;52:883–8. <https://doi.org/10.1038/bmt.2017.71>.
 17. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. *Blood Rev*. 2019;36:70–87. <https://doi.org/10.1016/j.blre.2019.04.005>.
 18. Bertoli S, Tavittian S, Huynh A, Borel C, Guenounou S, Luquet I, et al. Improved outcome for AML patients over the years 2000–2014. *Blood Cancer J*. 2017;7:635. <https://doi.org/10.1038/s41408-017-0011-1>.
 19. Ramadan SM, Suci S, Stevens-Kroef M, Willemze R, Amadori S, de Witte T, et al. Survival improvement over Time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. *Cancers (Basel)*. 2020;12:3334. <https://doi.org/10.3390/cancers12113334>.
 20. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. *Blood*. 2006;107:3481–5. <https://doi.org/10.1182/blood-2005-09-3724>.
 21. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129:424–47. <https://doi.org/10.1182/blood-2016-08-733196>.
 22. Gavazzi G, Krause KH. Ageing and infection. *Lancet Infect Dis*. 2002;2:659–66. [https://doi.org/10.1016/s1473-3099\(02\)00437-1](https://doi.org/10.1016/s1473-3099(02)00437-1).
 23. He W, Xiao K, Fang M, Xie L. Immune cell number, phenotype, and function in the elderly with sepsis. *Aging Dis*. 2021;12:277–96. <https://doi.org/10.14336/ad.2020.0627>.
 24. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. 2020;71:1367–76. <https://doi.org/10.1093/cid/ciz1008>.
 25. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med*. 2007;26:2389–430. <https://doi.org/10.1002/sim.2712>.
 26. Cox DR. Regression models and life-tables. *J Roy Stat Soc: Ser B (Methodol)*. 1972;34:187–220. <https://doi.org/10.1111/j.2517-6161.1972.tb00899.x>.
 27. Wreede LC, Fiocco M, Putter H. mstate: an R package for the analysis of competing risks and multi-state models. *J Stat Softw*. 2011;38:1–30. <https://doi.org/10.18637/jss.v038.i07>.
 28. Girmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. *Leuk Res*. 2014;38:469–74. <https://doi.org/10.1016/j.leukres.2014.01.007>.
 29. Segal BH. Aspergillosis. *N Engl J Med*. 2009;360:1870–84. <https://doi.org/10.1056/nejmra0808853>.
 30. van de Peppel RJ, de Boer MGJ. The complex case of aspergillus and mortality. *Clin Infect Dis*. 2019;68:531–2. <https://doi.org/10.1093/cid/ciy698>.
 31. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. *J Clin Oncol*. 2018;36:3043–54. <https://doi.org/10.1200/jco.18.00374>.
 32. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother*. 2018;73:3221–30. <https://doi.org/10.1093/jac/dky286>.
 33. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;63:e1–60. <https://doi.org/10.1093/cid/ciw326>.
 34. SWAB Invasive Fungal Infections Guidelines Committee (2017) SWAB Guidelines for the Management of Invasive Fungal Infections. Dutch Working Party on Antibiotic Policy (SWAB). <https://swab.nl/nl/invasieve-schimmelinfecties>. Accessed 14 Dec 2017.
 35. Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, et al. “Real-life” analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. *J Antimicrob Chemother*. 2019;74:1062–8. <https://doi.org/10.1093/jac/dky550>.
 36. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. *Haematologica*. 2010;95:644–50. <https://doi.org/10.3324/haematol.2009.012054>.
 37. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. *J Infect Dis*. 2002;186:1297–1306. <https://doi.org/10.1086/343804>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

